Retatrutide TRIUMPH-4: Joint Pain Relief Confirmed, a New Safety Signal Emerges
Retatrutide TRIUMPH-4 full data: 71 lbs average weight loss, knee pain reduced up to 75.8%, plus a dysesthesia signal at high doses worth honest scrutiny.
Researchers Scanned 410,000 Reddit Posts for GLP-1 Side Effects. Here’s What Doctors Are Missing.
Penn researchers analyzed 410,000 Reddit posts on GLP-1 drugs and surfaced reproductive and temperature symptoms missing from formal pharmacovigilance. The signal explained.
GLP-1 Drugs and Genetics: Why Response Varies So Much
GLP-1 genetic response: two 2026 studies show why weight loss ranges 6–20% and nausea risk ranges 5–78% on the same drug. The evidence, scoped honestly.
Tirzepatide’s Inventors Just Argued GLP-1 Isn’t Necessary for Weight Loss
Tirzepatide’s inventors propose a GIP/glucagon-only obesity drug, arguing GLP-1 activation may not be necessary for weight loss. The class-defying paper, scoped honestly.
FDA to Review Seven Peptides for 503A Compounding List at July PCAC Meeting
FDA’s PCAC will evaluate BPC-157, KPV, TB-500, and four more peptides for 503A compounding status July 23–24. What the evidence says and what it means.
The Three-Layered GLP-1 Access Crisis: Insurance Losses, a Medicare Delay, and a Pricing Experiment
24 million lost GLP-1 coverage, Medicare’s BALANCE Model delayed, MFN pricing at $245/month. Three forces reshaping who can afford weight loss drugs.
A “Gut Reset” Procedure May Prevent Weight Regain After Stopping GLP-1 Drugs—Here Is What the First Controlled Trial Found
First randomized sham-controlled trial shows duodenal mucosal resurfacing maintains 80%+ of weight loss after stopping tirzepatide. Full evidence review.
FDA Approves Wegovy HD: Higher-Dose Semaglutide Delivers 18.7% Weight Loss in Accelerated Review
FDA approved Wegovy HD (semaglutide 7.2 mg) via accelerated 54-day review. STEP UP trial shows 18.7% weight loss at 72 weeks. Full evidence breakdown.
What the April 22 FDA Category 2 Removal Actually Means (and Doesn’t)
What the April 22 FDA Category 2 Removal Actually Means (and Doesn’t) April 21, 2026 — one day before the
The FDA Is Naming Names: Warning Letters Hit Five Research Peptide Vendors
The FDA Is Naming Names: Warning Letters Hit Five Research Peptide Vendors The agency’s crackdown on gray-market peptide suppliers is